InsiderTrades.com logo

Jonathan Lieber Biography and Net Worth

CFO of Rallybio
  • LinkedIn
  • Phone
  • Email
  • Website


Jon is the Chief Financial Officer of Rallybio. He has more than 30 years of experience as a CFO for public and private life sciences companies and an investment banker. Most recently, he served as the CFO of Applied Genetic Technologies Corporation (AGTC), a publicly traded biotechnology gene therapy company focused on rare diseases, where he led all capital raising activities and was responsible for accounting and finance, human resources, investor relations, information technology and project management. Prior to AGTC, Jon was a Managing Director at Danforth Advisors, a private equity-backed firm, where he provided CFO services and strategic advice to public and private healthcare companies . Previously, he has served as CFO at firms including Histogenics, a publicly traded cell therapy company, Repligen, Xcellerex (acquired by GE Healthcare), and Altus Pharmaceuticals. Jon began his career in healthcare as an investment banker at Salomon Brothers / Salomon Smith Barney and SG Cowen.

Jon is a member of the board of directors of Salarius Pharmaceuticals and serves on the Audit and Nominating and Governance Committees.

Jon earned his Bachelor of Science in business administration and finance from Boston University and a master’s degree in finance from New York University’s Leonard N. Stern School of Business.

What is Jonathan I. Lieber's net worth?

The estimated net worth of Jonathan I. Lieber is at least $70.33 thousand as of February 23rd, 2026. Mr. Lieber owns 4,115 shares of Rallybio stock worth more than $70,325 as of September 17th. This net worth evaluation does not reflect any other investments that Mr. Lieber may own. Learn More about Jonathan I. Lieber's net worth.

How do I contact Jonathan I. Lieber?

The corporate mailing address for Mr. Lieber and other Rallybio executives is 234 Church Street, Suite 1020, New Haven, CT, 06510. Rallybio can also be reached via phone at (203) 859-3820 and via email at [email protected]. Learn More on Jonathan I. Lieber's contact information.

Has Jonathan I. Lieber been buying or selling shares of Rallybio?

Jonathan I. Lieber has not been actively trading shares of Rallybio in the last ninety days. Most recently, Jonathan I. Lieber sold 789 shares of the business's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $5.06, for a transaction totalling $3,992.34. Following the completion of the sale, the chief financial officer now directly owns 4,115 shares of the company's stock, valued at $20,821.90. Learn More on Jonathan I. Lieber's trading history.

Who are Rallybio's active insiders?

Rallybio's insider roster includes Jeffrey Fryer (Insider), Jonathan Lieber (CFO), Martin Mackay (CEO), and Stephen Uden (Insider). Learn More on Rallybio's active insiders.

Are insiders buying or selling shares of Rallybio?

In the last twelve months, Rallybio insiders bought shares 8 times. They purchased a total of 302,473 shares worth more than $4,229,715.11. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 789 shares worth more than $3,992.34. The most recent insider tranaction occured on May, 19th when Major Shareholder Adar1 Capital Management, Llc bought 10,200 shares worth more than $142,596.00. Insiders at Rallybio own 10.3% of the company. Learn More about insider trades at Rallybio.

Information on this page was last updated on 5/19/2026.

Jonathan I. Lieber Insider Trading History at Rallybio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/23/2026Sell789$5.06$3,992.344,115View SEC Filing Icon  
3/14/2023Buy625$41.68$26,050.00625View SEC Filing Icon  
See Full Table

Jonathan I. Lieber Buying and Selling Activity at Rallybio

This chart shows Jonathan I. Lieber's buying and selling at Rallybio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rallybio Company Overview

Rallybio logo
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Read More

Today's Range

Now: $16.93
Low: $17.18
High: $17.18

50 Day Range

MA: $16.54
Low: $15.73
High: $17.22

2 Week Range

Now: $16.93
Low: $3.67
High: $17.57

Volume

236 shs

Average Volume

141,776 shs

Market Capitalization

$89.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A